Bio
Esther is a postdoctoral research fellow in the Endogenous Peptide Lab within the Cardiovascular and Metabolic Disease Programme at Duke-NUS. She trained in infectious diseases during her PhD, focusing on preclinical vaccine and therapeutic development, and contributed to the discovery of novel monoclonal antibodies against Yellow Fever and Zika. During the COVID-19 pandemic, she collaborated with Arcturus Therapeutics on the development of the first self-amplifying mRNA vaccine licensed for human use. She is also a co-inventor of a gene therapy for genetic dilated cardiomyopathy developed in collaboration with Nuevocor Biotech. Esther joined the Endogenous Peptide Lab to drive commercialization and translational efforts for small endogenous peptides (SEPs) through a bridge programme with 65Labs and LIVE Ventures.
Education
Doctor of Philosophy
National University of Singapore, Singapore
Bachelor of Science in Biology
University of British Columbia, Singapore